Medicine and Dentistry
Acute Graft Rejection
13%
Allograft
36%
Alternariosis
15%
Antinociception
15%
Artery Reconstruction
9%
Ascites
15%
Bezoar
31%
Biopsy
11%
Bovine Serum Albumin
11%
Bowel Obstruction
18%
Calcineurin Inhibitor
19%
Cholestasis
15%
Cohort Analysis
15%
Contraindication
15%
Creatinine
10%
Cyclosporine
42%
Diabetes Mellitus
15%
Diverticulum
12%
Effective Kidney Plasma Flow
31%
Epidermal Growth Factor Receptor
15%
Everolimus
31%
Fifth Disease
15%
Glomerular Filtration Rate
27%
Hepatitis Virus
7%
Immune Checkpoint Inhibitor
15%
Immunosuppressive Treatment
26%
Incentive
15%
Ingestion
25%
Interim Analysis
15%
Jejunum Ulcer
12%
Kidney Function
16%
Kidney Graft
100%
Kidney Transplantation
34%
Liver Dysfunction
31%
Met-Enkephalin
15%
Morphine
15%
Mycophenolic Acid
19%
Nephrectomy
49%
Non Small Cell Lung Cancer
15%
Overall Survival
17%
Peliosis Hepatis
15%
Peroperative Complication
15%
Randomized Controlled Trial
15%
Renal Artery
21%
Reticulin
15%
Stomach Surgery
12%
Surgery
12%
Surgical Technique
27%
Targeted Therapy
9%
Transplantation
29%
Immunology and Microbiology
Alloantibody
18%
Allotransplantation
45%
Chronic Graft Rejection
35%
Ciclosporin
15%
Effective Kidney Plasma Flow
15%
ELISA
9%
Enzyme-Linked Immunosorbent Assay
21%
Epitope
7%
Everolimus
15%
Glomerulus Filtration
9%
HLA Antibody
47%
Human Leukocyte Antigen
67%
Immune Complex
49%
Immunosuppression
15%
Immunosuppressive Drug
17%
Immunosuppressive Therapy
5%
Kidney Transplantation
73%
Monospecific Antibody
34%
Mycophenolic Acid
17%
Plasmapheresis
5%
Titer
15%
Transplant Procedure
76%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Rejection
5%
Adverse Event
5%
Alternaria
7%
Alternariosis
15%
Antinociception
15%
Bezoar
31%
Chemotherapy
9%
Cholestasis
15%
Ciclosporin
58%
Cohort Study
15%
Diabetes Mellitus
15%
Diverticulosis
12%
Epidermal Growth Factor Receptor
15%
Erythema Infectiosum
15%
Everolimus
15%
Graft Failure
5%
Hepatitis C Virus
6%
Immunosuppressive Agent
10%
Infection
6%
Intestine Obstruction
18%
Jejunum Ulcer
12%
Liver Dysfunction
15%
Malignant Neoplasm
5%
Metenkephalin
15%
Morphine
15%
Mycophenolic Acid
47%
Non Small Cell Lung Cancer
15%
Obstruction
6%
Overall Survival
17%
Postmarketing Surveillance
15%
Randomized Controlled Trial
31%
Rapamycin
15%
Recurrent Disease
6%
Tacrolimus
31%
Ulcer
6%